福沙那韦联合利托那韦可增加血浆酮康唑和利托那韦的暴露量，而安普那韦的暴露量保持不变。
Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged.
作者信息
Wire Mary B, Ballow Charles H, Borland Julie, Shelton Mark J, Lou Yu, Yuen Geoffrey, Lin Jiang, Lewis Eric W
机构信息
Clinical Pharmacology and Discovery Medicine, GlaxoSmithKline, Research Triangle Park, NC 27709, USA.
出版信息
Antimicrob Agents Chemother. 2007 Aug;51(8):2982-4. doi: 10.1128/AAC.00008-07. Epub 2007 May 21.
Abstract
Plasma ketoconazole (KETO), amprenavir (APV), and ritonavir (RTV) pharmacokinetics were evaluated in 15 healthy subjects after being treated with KETO at 200 mg once daily (QD), fosamprenavir (FPV)/RTV at 700/100 mg twice daily (BID), and then KETO at 200 mg QD plus FPV/RTV at 700/100 mg BID in this open-label study. The KETO area under the concentration-time curve at steady state was increased 2.69-fold with FPV/RTV. APV exposure was unchanged, and RTV exposure was slightly increased.
摘要
在这项开放标签研究中，对15名健康受试者进行了血浆酮康唑（KETO）、安普那韦（APV）和利托那韦（RTV）的药代动力学评估。受试者先接受每日一次200毫克的酮康唑治疗，然后接受每日两次700/100毫克的福沙普那韦（FPV）/利托那韦治疗，最后接受每日一次200毫克的酮康唑加每日两次700/100毫克的福沙普那韦/利托那韦治疗。与福沙普那韦/利托那韦联用时，稳态下酮康唑的浓度-时间曲线下面积增加了2.69倍。安普那韦的暴露量未改变，利托那韦的暴露量略有增加。
相似文献
1
Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged.福沙那韦联合利托那韦可增加血浆酮康唑和利托那韦的暴露量，而安普那韦的暴露量保持不变。
Antimicrob Agents Chemother. 2007 Aug;51(8):2982-4. doi: 10.1128/AAC.00008-07. Epub 2007 May 21.
2
Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir.福沙普那韦与利托那韦高剂量组合的药代动力学及安全性评估
Antimicrob Agents Chemother. 2006 Mar;50(3):928-34. doi: 10.1128/AAC.50.3.928-934.2006.
3
Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.在健康志愿者中，每日一次给予1400毫克福沙那韦与100或200毫克利托那韦联合用药后，血浆安普那韦的药代动力学和耐受性。
Antimicrob Agents Chemother. 2007 Feb;51(2):560-5. doi: 10.1128/AAC.00560-06. Epub 2006 Nov 6.
4
Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.在健康志愿者中，未增强或利托那韦增强福沙那韦与富马酸替诺福韦二吡呋酯合用后，稳态安普那韦和替诺福韦的药代动力学。
HIV Med. 2010 Mar;11(3):193-9. doi: 10.1111/j.1468-1293.2009.00765.x. Epub 2009 Oct 23.
5
Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV.与福沙那韦或安普那韦合用时，利托那韦可使血浆安普那韦（APV）暴露量增加至相似程度。
Antimicrob Agents Chemother. 2006 Apr;50(4):1578-80. doi: 10.1128/AAC.50.4.1578-1580.2006.
6
Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.福沙普瑞那韦/利托那韦每日一次用于初治HIV-1感染患者的长期（120周）抗病毒疗效及耐受性：一项非对照、开放标签、单臂随访研究
Clin Ther. 2006 May;28(5):745-54. doi: 10.1016/j.clinthera.2006.05.011.
7
Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.在人类免疫缺陷病毒阴性受试者中同时给予福沙普那韦和阿扎那韦（不联用利托那韦）的药代动力学
Pharmacotherapy. 2009 Aug;29(8):937-42. doi: 10.1592/phco.29.8.937.
8
Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.健康志愿者中，每日一次服用福沙普那韦/利托那韦、阿扎那韦/利托那韦单药及与20毫克奥美拉唑联合用药的稳态药代动力学。
HIV Med. 2007 Oct;8(7):457-64. doi: 10.1111/j.1468-1293.2007.00496.x.
9
Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.福沙普那韦/利托那韦治疗晚期HIV疾病（TRIAD）：一项针对具有抗逆转录病毒耐药性的HIV-1感染患者，对比高剂量、双重增效或标准剂量福沙普那韦/利托那韦的随机研究。
J Antimicrob Chemother. 2009 Aug;64(2):398-410. doi: 10.1093/jac/dkp198. Epub 2009 Jun 10.
10
Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.在接受福沙普那韦/利托那韦治疗且有不同程度肝功能损害的HIV感染患者中安普那韦和利托那韦的血浆浓度
J Antimicrob Chemother. 2007 Oct;60(4):831-6. doi: 10.1093/jac/dkm282. Epub 2007 Aug 7.
引用本文的文献
1
Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects.福沙普那韦-利托那韦对健康受试者中多替拉韦药代动力学的影响。
Antimicrob Agents Chemother. 2014 Nov;58(11):6696-700. doi: 10.1128/AAC.03282-14. Epub 2014 Aug 25.
2
Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir.HIV 整合酶抑制剂艾维雷格的临床药代动力学和药效学特征。
Clin Pharmacokinet. 2011 Apr;50(4):229-44. doi: 10.2165/11584570-000000000-00000.
3
A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer.一项高剂量酮康唑联合每周多西他赛治疗转移性去势抵抗性前列腺癌的 I 期临床研究。
J Urol. 2010 Jun;183(6):2219-26. doi: 10.1016/j.juro.2010.02.020.
本文引用的文献
1
Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus.酮康唑对感染人类免疫缺陷病毒患者血浆和脑脊液中利托那韦及沙奎那韦浓度的影响。
Clin Pharmacol Ther. 2000 Dec;68(6):637-46. doi: 10.1067/mcp.2000.112363.
2
Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men.
Pharmacotherapy. 1999 Dec;19(12):1378-84. doi: 10.1592/phco.19.18.1378.30905.
Zotero 插件